Sanofi (EPA:SAN)

France flag France · Delayed Price · Currency is EUR
84.84
-0.94 (-1.10%)
Oct 7, 2025, 5:35 PM CET
-1.10%
Market Cap103.23B
Revenue (ttm)45.74B
Net Income (ttm)9.13B
Shares Out1.22B
EPS (ttm)7.36
PE Ratio16.47
Forward PE10.51
Dividend3.92 (4.57%)
Ex-Dividend DateMay 12, 2025
Volume1,678,564
Average Volume2,077,722
Open84.95
Previous Close85.78
Day's Range84.29 - 85.34
52-Week Range76.15 - 110.88
Beta0.44
RSI59.06
Earnings DateOct 24, 2025

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange Euronext Paris
Ticker Symbol SAN
Full Company Profile

Financial Performance

In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.

Financial Statements

News

Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M

Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M

7 hours ago - GuruFocus

Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax

Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax

10 hours ago - GuruFocus

AstraZeneca Taps Gene Editing And AI Platform For Drug Discovery For Immunology Diseases

Algen Biotechnologies , a privately held biotech company specializing in advanced CRISPR gene modulation and AI-driven drug discovery, has announced a multi-target partnership with AstraZeneca Plc (NA...

1 day ago - Benzinga

Bullish Two Hundred Day Moving Average Cross - SNY

In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $50.89, changing hands as high as $51.05 per share. Sanofi shares are currently trading up about 1.7%...

4 days ago - Nasdaq

Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay

Sanofi (SNY) Supports Revvity's Expansion in Type 1 Diabetes Assay

5 days ago - GuruFocus

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...

5 days ago - Business Wire

Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices

Sanofi (SNY) Under EU Antitrust Investigation Over Vaccine Practices

6 days ago - GuruFocus

Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...

6 days ago - The Guardian

QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials

TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g...

6 days ago - Business Wire

Novavax (NVAX) Expands License for Matrix-M with Sanofi

Novavax (NVAX) Expands License for Matrix-M with Sanofi

7 days ago - GuruFocus

Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended thei...

7 days ago - Nasdaq

MoonLake Immunotherapeutics Stock Plummets After Phase 3 Data Readouts

MoonLake Immunotherapeutics ‘ (NASDAQ: MLTX) stock price fell off a cliff Monday after it reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials . The trials used HiSCR75—a 75% reduction ...

8 days ago - Benzinga

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma Wal...

8 days ago - Benzinga

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...

11 days ago - Seeking Alpha

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S...

11 days ago - Benzinga

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation ... Full story available on Benzinga.com

11 days ago - Benzinga

Sanofi (SNY) Expands Affordable Insulin Access Program

Sanofi (SNY) Expands Affordable Insulin Access Program

11 days ago - GuruFocus

Sanofi (SNY) Broadens Insulin Savings Program Nationwide

Sanofi (SNY) Broadens Insulin Savings Program Nationwide

11 days ago - GuruFocus

Sanofi to offer all insulin products for $35 per month in US

French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.

11 days ago - Reuters

Sanofi Expands $35 Insulin Program To All U.S. Patients

(RTTNews) - Sanofi (SNY) on Friday announced a broad expansion of its Insulins Valyou Savings Program, under which a 30-day supply of any Sanofi insulin will be available for $35 to all U.S. patients ...

11 days ago - Nasdaq

Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

MORRISTOWN, N.J. , Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all pa...

11 days ago - PRNewsWire